Nasif Islam, Ph.D.
Director, Strategy and Business Development at Priovant Therapeutics- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Credentials
-
Series 79
FINRAAug, 2021- Sep, 2024 -
Securities Industry Essentials (SIE)
FINRAJun, 2021- Sep, 2024
Experience
-
Priovant Therapeutics
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Director, Strategy and Business Development
-
2022 - Present
-
-
-
Credit Suisse
-
Switzerland
-
Banking
-
700 & Above Employee
-
Investment Banking Associate
-
2021 - 2022
Global Healthcare Investment Banking Group Global Healthcare Investment Banking Group
-
-
-
TRINITY
-
United Kingdom
-
Leasing Non-residential Real Estate
-
1 - 100 Employee
-
Senior Consultant
-
2020 - 2021
Worked on a broad range of strategy projects for biopharma and biotech clients including: - Built a robust competitive intelligence program for biosimilars in oncology and immunology - Designed the go-to-market strategy for a small-cap pharmaco's rare disease drug - Assessed the value of an oncology asset from a payer perspective for a large-cap pharmaco - Identified commercially attractive rare indications for a novel oligonucleotide delivery platform - Developed a commercial landscape assessment of the NASH market for a mid-cap pharmaco - Created a roadmap of the development landscape for a drug being repurposed for COVID-19 Show less
-
-
-
Tata Communications
-
India
-
Telecommunications
-
700 & Above Employee
-
Corporate Venture Capital Scout
-
May 2019 - Aug 2019
-
-
-
Stanford University School of Medicine
-
Hospitals and Health Care
-
1 - 100 Employee
-
Amgen Foundation Scholar
-
May 2013 - Aug 2013
-
-
Education
-
The Johns Hopkins University School of Medicine
Doctor of Philosophy - PhD, Biochemistry, Cellular and Molecular Biology -
Cornell University
Bachelor of Science - BS